Biotechnology company Biogen Inc. (Nasdaq:BIIB) announced on Tuesday that it has finalized the acquisition of Human Immunology Biosciences (HI-Bio), a clinical-stage biotech specializing in targeted therapies for severe immune-mediated diseases (IMDs).

The addition of felzartamab bolsters Biogen's immunology pipeline, offering a promising late-stage candidate across multiple indications. Collaboration with HI-Bio will focus on advancing felzartamab to phase 3, aiming to deliver innovative treatments for rare diseases with unmet needs.

Integrating HI-Bio into Biogen leverages the company's global infrastructure to support felzartamab's development and expands our immunology portfolio. Positive interim results from Phase 2 studies in IgA nephropathy (IgAN) and antibody-mediated rejection (AMR) were presented at the European Renal Association Congress and published in the New England Journal of Medicine. Phase 2 proof-of-concept in primary membranous nephropathy (PMN) underscores plans to progress felzartamab to Phase 3 across AMR, IgAN, and PMN.